July 15, 2014 | The US Food and Drug Administration (FDA) is set to review Teva Pharmaceutical Industries‘ drug application for the treatment of asthma, the albuterol multi-dose dry-powder inhaler (MDPI). According to a “Globes” report, the inhaler will be used to treat patients of 12 years of age or older for bronchospasm. Teva VP of Global Respiratory R&D Tushar Shah said, “If approved, albuterol MDPI would become the first breath-actuated dry-powder symptomatic and rescue inhaler available to asthma patients. As the current market-leader in asthma rescue inhalers, it is our hope that the new dry-powder innovation utilized with albuterol MDPI will help fill an unmet need in the existing asthma market.”
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Israel Foodtech Firms Meet UK Retailers, Investors In London
April 17, 2024
Facebook comments